Molecular Pharmacology Program
The Daniel Heller Lab
Research

Cancer Nanomedicine Laboratory
We are inventing novel technologies to treat advanced cancers and to detect disease at early stages. We are a young bioengineering laboratory that develops new nanotechnologies, including nanomedicines—tiny particles that target drugs to tumor sites, and nanosensors—tiny devices that detect markers of disease. Please check out our recent innovations using the “Learn more” button below…
Research Projects
Inside My Lab: Daniel Heller

Featured News
Publications
People

Daniel A. Heller, PhD
- Chemist Daniel Heller focuses on biomaterials and nanoscale engineering for molecular sensors and targeted therapeutics.
- PhD, University of Illinois at Urbana-Champaign
- [email protected]
- Email Address
- 646-888-3438
- Office Phone
- Download CV
- PDF File
Members

- PhD in Engineering and Bioengineering














- BS in Chemistry from The College of New Jersey, Ewing NJ (2019)


- B.Sc in Biochemical Engineering
- M.Sc in Chemical Engineering
- Ph.D in Chemical Engineering
- 646-888-3416
- Lab Phone

Lab Head

Research Scholar

Research Fellow

Research Technician

Graduate Student

Graduate Research Assistant

Graduate Student

Research Fellow

Research Scholar

Research Fellow

Pediatric Hematology/Oncology Fellow

Research Fellow

Graduate Student

Graduate Student

Research Scholar

Research Scholar

Senior Research Technician

Graduate Student

Graduate Student

Graduate Student

Administrative Assistant

Research Scholar

- BS in Biochemistry
- PhD, Weill Graduate School of Medical Sciences, Cornell University
- 646-888-3416
- Lab Phone

- Massachusetts Institute of Technology 2013
- 646-888-3416
- Lab Phone

- PhD in Chemical Engineering
- 401.874.2678
- Office Phone

- PhD in Pharmaceutical and Pharmacological Sciences
Lab Alumni

Clinical Nurse

Research Scholar

Research Scholar

Visiting Scientist

Assistant Professor

Research Technician

Research Technician

Research Fellow

Graduate Student

Research Fellow
Summer Undergraduate Research Student

Lab Affilations
Achievements
- American Institute for Medical and Biological Engineering (AIMBE) Fellow (2021)
- Pharmacology Teaching and Mentoring Award, Weill Cornell Graduate School (2020)
- American Cancer Society Research Scholar (2018)
- NSF CAREER Award (2018)
- Pershing Square Sohn Prize for Young Innovators in Cancer Research (2017)
Read more
- NIH Director’s New Innovator Award (2012)
- Damon Runyon Cancer Research Foundation Postdoctoral Fellowship (2010)
- Beckman Institute Graduate Fellowship (2006)
Lab News & Events
Upcoming event
Nanotechnology Approaches for Drug Delivery to the Brain
This seminar will be conducted by Zoom Webinar.
Accolades
Team Recognitions
-
Congratulations to Dr. Mijin Kim - Kravis WiSE Postdoctoral Fellowship Winner! She is speaking March 17, 2021 at the 2nd annual Kravis WiSE Symposium.
Get in Touch
-
Lab Head Email
-
Office Phone
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Daniel A. Heller discloses the following relationships and financial interests:
-
Concarlo Holdings, LLC
Provision of Services -
Goldilocks Therapeutics Inc.
Intellectual Property Rights; Ownership / Equity Interests; Provision of Services (uncompensated) -
LipidSense, Inc.
Intellectual Property Rights; Ownership / Equity Interests -
Nanorobotics, Inc.
Ownership / Equity Interests
-
Nirova BioSense, Inc.
Intellectual Property Rights; Ownership / Equity Interests -
Photon etc.
Provision of Services (uncompensated) -
Zeno Pharmaceuticals, Inc.
Ownership / Equity Interests
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].